IL10 resistant PGS2 expression in at-risk/Type 1 diabetic human monocytes

Area of Science:

• Immunology
• Endocrinology
• Molecular Biology

Background:

• Aberrant prostaglandin synthase 2 (PGS2/COX2) expression in monocytes is linked to antigen presenting cell (APC) dysfunction in Type 1 diabetes.
• Granulocyte-monocyte colony stimulating factor (GM-CSF) activation promotes PGS2 expression during endotoxin activation in healthy monocytes.
• GM-CSF is a key target for Interleukin-10 (IL10) in suppressing PGS2.

Purpose of the Study:

• To investigate the role of IL10 resistance in PGS2 dysregulation in monocytes from individuals at risk for or with Type 1 diabetes.
• To examine the relationship between IL10 resistance, GM-CSF production, and other monocyte factors in Type 1 diabetes.

Main Methods:

• Monocyte cultures from Type 1 diabetes patients and healthy controls were analyzed.
• PGS2 expression was measured following IL10 suppression.
• GM-CSF production and other monocyte factors (DR, IL1beta, TNFalpha, IL12, CD54, CD64) were quantified.

Main Results:

• Monocytes from 47% of at-risk and diabetic individuals showed high resistance to IL10 suppression of PGS2.
• These resistant monocytes exhibited significantly increased GM-CSF production compared to controls.
• IL10's regulation of GM-CSF and other monocyte factors remained intact, indicating specific PGS2 insensitivity.

Conclusions:

• The inability of IL10 to downregulate PGS2 gene expression may be a contributing factor to Type 1 diabetes pathogenesis.
• Monocyte dysfunction, characterized by IL10-resistant PGS2, presents a potential therapeutic target.
• Further research is warranted to elucidate the precise mechanisms of PGS2 dysregulation in Type 1 diabetes.